<DOC>
	<DOCNO>NCT01913951</DOCNO>
	<brief_summary>This phase I trial study side effect best dose vosaroxin give together azacitidine treat patient myelodysplastic syndrome . Drugs use chemotherapy , vosaroxin azacitidine , work different way stop growth cancer cell , either kill cell stop dividing .</brief_summary>
	<brief_title>Vosaroxin Azacitidine Treating Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Diagnosis myelodysplastic syndrome one following : Cytopenias require red blood cell and/or platelet transfusion neutropenia ( ANC &lt; 1 X109/L ) IPSS score INT1 high screen MDS excess blast transformation define FAB criterion ( 2029 % bone marrow blast ) Chronic myelomonocytic leukemia Age ≥18 year old Adequate renal hepatic function define follow : total bilirubin ≤ 2.0 mg/dl , except case Gilbert 's disease ; AST ALT ≤2.5 institutional ULN ; serum creatinine within normal institutional limit estimate creatinine clearance ≥60 mL/min/1.73 m2 CockcroftGault equation ECOG performance status ≤2 Ability understand willingness sign IRB approve write informed consent document ( legally authorize representative , applicable ) . Females must surgically biologically sterile postmenopausal childbearing potential , must agree use adequate method contraception study 30 day last treatment . Males must surgically biologically sterile agree use adequate method contraception study 30 day last treatment . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately . Patients may receive 3 prior cycle hypomethylator therapy ( i.e . decitabine azacitidine ) prior enrollment may receive supportive care measure ( growth factor , erythropoietin stimulate agent , transfusion , etc . Either enrol HRPO # 201011766 ( `` Tissue Acquisition Analysis Genetic Progression Factors Hematologic Diseases '' ) , facilitate collection blood , bone marrow , skin correlative study , consent collection blood , bone marrow , skin part protocol . Prior treatment four cycle hypomethylator therapy . Receiving concomitant chemotherapy , radiation therapy , immunotherapy duration treatment protocol . Known seropositivity active viral infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) . Patients seropositive hepatitis B virus vaccine eligible . Patients seropositive HCV , negative viral load also eligible . Documentation patient complete course therapy HCV require obtain . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant and/or breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>